| 纯度 | >90%SDS-PAGE. |
| 种属 | E.coli |
| 靶点 | botB |
| Uniprot No | P10844 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-427aa |
| 氨基酸序列 | MPVTINNFNYNDPIDNNNIIMMEPPFARGTGRYYKAFKITDRIWIIPERYTFGYKPEDFNKSSGIFNRDVCEYYDPDYLNTNDKKNIFLQTMIKLFNRIKSKPLGEKLLEMIINGIPYLGDRRVPLEEFNTNIASVTVNKLISNPGEVERKKGIFANLIIFGPGPVLNENETIDIGIQNHFASREGFGGIMQMKFCPEYVSVFNNVQENKGASIFNRRGYFSDPALILMHELIHVLHGLYGIKVDDLPIVPNEKKFFMQSTDAIQAEELYTFGGQDPSIITPSTDKSIYDKVLQNFRGIVDRLNKVLVCISDPNININIYKNKFKDKYKFVEDSEGKYSIDVESFDKLYKSLMFGFTETNIAENYKIKTRASYFSDSLPPVKIKNLLDNEIYTIEEGFNISDKDMEKEYRGQNKAINKQAYEEISKE |
| 预测分子量 | 51.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于botB重组蛋白的模拟参考文献示例(仅供参考，非真实文献)：
1. **《High-Yield Expression and Purification of Recombinant Botulinum Neurotoxin Serotype B in Pichia pastoris》**
- 作者：Müller, J., et al.
- 摘要：研究通过毕赤酵母表达系统高效生产重组BoNT/B重链蛋白，优化发酵条件及纯化工艺，获得高纯度蛋白用于免疫学分析。
2. **《Crystal Structure of Recombinant Botulinum Toxin B Light Chain Reveals Substrate-Binding Mechanism》**
- 作者：Chen, L., & Singh, A.K.
- 摘要：解析了重组BoNT/B轻链的晶体结构，揭示了其与底物SNARE蛋白的结合位点，为抑制剂的理性设计提供结构基础。
3. **《Immunogenic Response to Recombinant BotB Subunit Vaccine in Murine Models》**
- 作者：Gupta, R., et al.
- 摘要：评估重组BoNT/B受体结合结构域(Hc)的免疫原性，证明其在小鼠模型中能诱导中和抗体，提示其作为预防性疫苗的潜力。
4. **《Functional Characterization of Recombinant BotB in Neuronal Cell Targeting》**
- 作者：Watanabe, T., et al.
- 摘要：利用重组BoNT/B蛋白的靶向特性，开发新型神经递质载体系统，验证其在体外神经元中的特异性结合与内化效率。
**建议**：实际文献可通过PubMed、Google Scholar等平台检索关键词“recombinant botulinum neurotoxin B”或“BoNT/B recombinant protein”获取。
**Background of BotB Recombinant Protein**
Botulinum neurotoxin type B (BoNT/B), produced by *Clostridium botulinum*, is a potent neurotoxin known for blocking acetylcholine release at neuromuscular junctions, leading to muscle paralysis. Historically, BoNT/B has been studied for its role in botulism, a severe neuroparalytic illness. However, its controlled application has therapeutic value, particularly in treating cervical dystonia and chronic migraines.
Traditional BoNT/B production relies on toxin extraction from bacterial cultures, a process with inherent biosafety risks and scalability challenges. Recombinant BoNT/B (botB) technology addresses these limitations by expressing the protein in heterologous systems like *E. coli* or yeast. This approach involves cloning the botB gene, encoding the light chain (LC) and heavy chain (HC) domains, into expression vectors. Post-translationally, the protein is processed to mimic the native toxin’s structure while maintaining its receptor-binding (HC) and catalytic (LC) functions.
Recombinant botB offers enhanced safety by eliminating reliance on pathogenic bacteria. It also enables precise engineering, such as mutating toxic residues (e.g., catalytic zinc-binding sites) to create detoxified variants for research or vaccine development. These variants retain immunogenicity without causing paralysis, making them valuable for antibody production and mechanistic studies.
Beyond therapeutics, recombinant botB serves as a tool to study synaptic vesicle trafficking and neurotransmitter release. Its scalability and purity improve consistency in research and drug formulation. Ongoing efforts focus on optimizing expression yields, stability, and delivery systems to expand its clinical potential, including novel neuropathic pain treatments or targeted therapies.
In summary, recombinant botB combines the functional properties of natural BoNT/B with the advantages of modern biotechnology, offering a safer, customizable platform for both therapeutic innovation and basic neuroscience research.
×
